FDA grants orphan drug designation for potential scleroderma treatment
The FDA has granted orphan drug designation to BLR-200, an investigational therapy for the treatment of scleroderma, according to a press release from manufacturer. The drug, a CCN3-derived peptide, is being developed by BLR Bio as part of the Helix 51 Bioscience Incubator at Rosalind Franklin University of Science and Medicine, in North Chicago, Illinois.